Summary: Thrombopoietin receptor (c-Mpl) is considered to regulate megakaryocytopoiesis. In this study, we investigated an effect of activation of a protein kinase C (PKC) on c-mpl promoter activity to elucidate the underlying mechanisms of c-mpl gene expression in megakaryoblastic cells. PKC is a member of a family of serine/threonine protein kinases in the cytosol involved in cell growth and differentiation. Phorbol 12-myristate 13-acetate (PMA) is known as PKC activator, significantly enhanced the c-mpl promoter activity and PKC inhibitors (H7, GF109203) suppressed the up-regulation of PMAinduced promoter activity and reduced the steady level of its activity. These results strongly suggest that PKC plays the essential role in the modulation of c-mpl promoter activity of megakaryoblastic cells.
Introduction
Thrombopoietin (TPO), a ligand for the c-Mpl receptor plays a crucial role in normal megakaryopoiesis and platelet development (De Sauvage et al., 1994 1) , Lok et al., 1994 2) , Wendling et al., 1994 3) , Kaushansky, 1999 4) ). PKC is a member of a family of serine/threonine protein kinases in the cytosol involved in pleiotropic processes such as cell growth, differentiation, and cytokine secretion (Ohno et al., 1991 5) , Nishizuka et al., 1992 6) ). The human megakaryoblastic cell line, CMK was established from the peripheral cells obtained from a patient with acute megakaryoblastic leukemia and Down' syndrome (Komatsu et al., 1989 7) , Sato et al., 1989 8) ). We previously characterized an expression of c-Mpl on the CMK cells (Sato et al., 1989 8) ) and found that TPO down-regulated the expression of c-Mpl on the cell surface (Sato et al., 1998 9) ). TPO has also been shown to activate PKC in the CMK cells (Hong et al., 1998 10) ). Previously, we reported that TPO-induced c-mpl promoter activity was modulated at transcription level through a PKC-dependent pathway in the CMK cells (Sunohara et al., 2003 11) ). In this research, we examined the effect of phorbol 12-myristate 13-acetate (PMA) on c-mpl promoter activity in the CMK cells to elucidate the role of PKC in modulation of c-mpl promoter activity.
Materials and methods

Cell Culture
CMK cells were cultured in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B at 37°C in humidified air containing 5% CO 2 atmosphere. Co., La Jolla, CA), was dissolved in DMSO as a stock solution and kept at −80°C until use. Control medium including DMSO at the highest concentration used in the stock solution was confirmed to have no effect on c-mpl gene expression.
Reagents
Construction of a reporter plasmid to measure the c-mplpromoter activity.
As described previously (Sunohara et al., 2003 11) ), the 310 bp upstream promoter region of c-mpl was amplified from the chromosomal DNA of the CMK cells by polymerase chain reaction using the following primer set, (forward 5'-CTA TTC TGA TGC TAT TAT ACC ATT C-3', reverse 5'-CTT GGC TGC TGA CTT GGG C-3'). The PCR product was cloned into pGEM-Teasy vector (Promega, Madison, WI) and designated as pGEM-c-mplprom. For the determination of the promoter activity of c-mpl, a Bgl II /Hind III fragment of pGEM-c-mpl-prom was subcloned into a defined Bgl II /Hind III site of the pGL3-basic vector (Promega) to construct pGL3-c-mpl (-310) in which the luciferase gene was driven under control of the c-mpl promoter.
Transient transfection assay
Three reporter plasmids, pGL3-basic vector (as a negative control), pGL3-control vector in which the luciferase gene is driven under SV40 promoter (as a positive control, Promega) and the pGL3-c-mpl (-310) were used for transfection assay. A plasmid, pRL-CMV (TOYO INC MFG CO., LTD., Tokyo), which expresses Renilla (SeaPansy) luciferase under control of CMV early promoter, was used to normalize the transfection efficiency. PMA (20 nM) was added to the CMK cells and then the cells were washed twice in PBS. The reporter plasmids (1 µg) were co-transfected with the pRL-CMV into the CMK cells for 5 h by a lipofection method using the DMRIE-C reagent (GIBCO, Grand Island, NY) according to the manufacturer's instructions. Then, the cells were cultured in the growth medium (RPMI1640, 10% FCS) for 19 h, washed twice in PBS, lyzed in a cell lysis reagent, LCß (TOYO INC MFG CO., LTD., Tokyo) and stored at −80°C until luciferase assay. The luciferase activity was quantified by using a PicaGene-Dual-SeaPansy Luminescence Kit (TOYO INC MFG CO., LTD., Tokyo). Twenty µl aliquot of cell lysates were added to 100 µl of luciferase reaction mixture supplied in the kit, and luciferase activity was measured with a luminometer in accordance with the manufacturer's instructions. The cell lysate of the cells transfected with a promoter-less control vector, pGL3-Basic Vector, was used as a negative control and the SeaPansy luciferase activity expressed from pRL-CMV was used to evaluate transfection efficiency and to normalize luciferase activity in all lysates. Results are expressed as the percentage of the control values. All the experiments were performed at least three times, and results represent means ± SD of at least 3 measurements.
Results
Effect of time period of PMA treatment on the activation of the c-mpl promoter
The induction of the c-mpl gene was found to be transient. Maximal promoter activity was obtained by PMA pretreatment for 3 h and longer pretreatments did not result in up-regulation of c-mpl promoter activity (Fig. 1) .
Time-dependent effect of PMA on the activation of the c-mpl promoter
The c-mpl promoter activity in PMA-treated cells (20 nM for 3 h) reached a maximal level at 24 h and then declined gradually until 72 h (Fig. 2) . Thus, induction of the c-mpl gene was transient in time. 
Effect of PKC inhibitors on the PMA-induced c-mpl promoter activity
To test the role of PKC in PMA-induced c-mpl promoter activity, PKC inhibitors [H7 (100 µM) and GF109203 (10 µM)] were added to the CMK cells 1h before PMA pretreatment (20 nM for 3 h). The cells were washed twice, then transfected with pGL3-c-mpl (-310) for 5 h and incubated in the growth medium for 19 h and then c-mpl promoter activity was measured. As shown in Fig. 3 , both H7 and GF109203 completely inhibited the PMA-induced activation of c-mpl promoter.
Discussion
Previously, we investigated the effect of TPO treatment on c-mpl gene expression and reported that the promoter activity of c-mpl was up-regulated by TPO pretreatment. We also confirmed that this TPO induced upregulation was completely abolished by treatment with PKC inhibitors. The PKC dependent pathway was shown to be involved not only in the process for the up-regulation of c-mpl promoter activity but also in a feed back regulatory mechanism for c-mpl expression itself in the megakaryoblastic CMK cells (Sunohara et al., 2003 11) ). TPO-induced down-regulation of c-Mpl on the cell surface might be the trigger for the up-regulation of the c-mpl promoter activity (Sato et al., 1998 9) ). In this study, to further explore the role of PKC in c-mpl gene expression, we examined the effect of the PKC activator, phorbol 12-myristate 13-acetate (PMA) on c-mpl promoter activity in the CMK cells. As shown in Fig. 3 , PMA significantly elevated the c-mpl promoter activity, while H7 and GF109203, both known as PKC inhibitors, suppressed the up-regulation of PMA-induced promoter activity and reduced the steady level of its activity.
Thus the results clearly suggest that PKC plays the key role in the modulation of c-mpl promoter activity in the human megakaryoblastic CMK cells.
Further investigation is required to elucidate the precise interaction between cellular transactivators and the binding motifs within the c-mpl promoter resulting in the activation of the promoter in human megakaryoblastic cells. 
